Follow Forum_Psych on Twitter

Display results as :

Rechercher Advanced Search

We have 222 registered users
The newest registered user is raheelmemon

Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.

Which antidepressant is best option for major depressive disorder in children and adolescents

Go down

Which antidepressant is best option for major depressive disorder in children and adolescents

Post  Admin on Thu Jun 09, 2016 5:31 pm

Q: Which antidepressant is best option for major depressive disorder in children and adolescents?

A network meta-analysis published in Lacent online on 08 June 2016 (source below). This network meta-analysis was done to identify both direct and indirect evidence from relevant trials. 

* Searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. 
* Trials included for: amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. 
* Exclusion criteria: Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patient. 

* Found 34 eligible trials= 5260 participants and 14 antidepressant treatments
* The quality of evidence was rated as very low in most comparisons. 
* For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference −0·51, 95% credible interval [CrI] −0·99 to −0·03). 
* For tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). 
* Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively).

Interpretation provided by authors:

(1) When considering the risk–benefit profile of antidepressants in the acute treatment of major depressive disorder, antidepressants do not seem to offer a clear advantage for children and adolescents

(2) Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.

Source: Source: Cipriani et al., Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet Published Online: 08 June 2016.

Click on to post your comments

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

Back to top Go down

Back to top

- Similar topics

Permissions in this forum:
You cannot reply to topics in this forum